269 related articles for article (PubMed ID: 8944370)
41. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
Almer S; Norlander B; Ström M; Osterwald H
Scand J Gastroenterol; 1991 Mar; 26(3):327-35. PubMed ID: 1853156
[TBL] [Abstract][Full Text] [Related]
42. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.
Mantzaris GJ; Hatzis A; Petraki K; Spiliadi C; Triantaphyllou G
Dis Colon Rectum; 1994 Jan; 37(1):58-62. PubMed ID: 8287749
[TBL] [Abstract][Full Text] [Related]
43. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
44. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
45. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Marshall JK; Irvine EJ
Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
[TBL] [Abstract][Full Text] [Related]
46. Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses.
Knoll U; Strauhs P; Schusser G; Ungemach FR
J Vet Pharmacol Ther; 2002 Apr; 25(2):135-43. PubMed ID: 12000534
[TBL] [Abstract][Full Text] [Related]
47. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
Hawkey CJ; Dube LM; Rountree LV; Linnen PJ; Lancaster JF
Gastroenterology; 1997 Mar; 112(3):718-24. PubMed ID: 9041232
[TBL] [Abstract][Full Text] [Related]
48. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Kane SV; Bjorkman DJ
Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
[TBL] [Abstract][Full Text] [Related]
49. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
[TBL] [Abstract][Full Text] [Related]
50. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
d'Albasio G; Pacini F; Camarri E; Messori A; Trallori G; Bonanomi AG; Bardazzi G; Milla M; Ferrero S; Biagini M; Quaranta S; Amorosi A
Am J Gastroenterol; 1997 Jul; 92(7):1143-7. PubMed ID: 9219787
[TBL] [Abstract][Full Text] [Related]
51. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis.
Bardazzi G; d'Albasio G; Bonanomi AG; Trallori G; Messori A; Amorosi A; Bartoletti L; Morettini A; Pacini F
Ital J Gastroenterol; 1994 Sep; 26(7):334-7. PubMed ID: 7812025
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
Norlander B; Gotthard R; Ström M
Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
[TBL] [Abstract][Full Text] [Related]
53. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
54. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
55. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
Kam L; Cohen H; Dooley C; Rubin P; Orchard J
Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
[TBL] [Abstract][Full Text] [Related]
56. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
Mahmud N; Kamm MA; Dupas JL; Jewell DP; O'Morain CA; Weir DG; Kelleher D
Gut; 2001 Oct; 49(4):552-6. PubMed ID: 11559654
[TBL] [Abstract][Full Text] [Related]
57. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.
Wadworth AN; Fitton A
Drugs; 1991 Apr; 41(4):647-64. PubMed ID: 1711964
[TBL] [Abstract][Full Text] [Related]
58. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.
Lee FI; Jewell DP; Mani V; Keighley MR; Kingston RD; Record CO; Grace RH; Daniels S; Patterson J; Smith K
Gut; 1996 Feb; 38(2):229-33. PubMed ID: 8801202
[TBL] [Abstract][Full Text] [Related]
59. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
[TBL] [Abstract][Full Text] [Related]
60. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
